Search Results

中文版 ICH E1 人群暴露程度：评价无生命威胁条件下长期治疗药物的临床安全性 The objective of this guideline is to present an accepted set of principles for the safety evaluation of drugs intended for the long-term treatment (chronic or repeated intermittent use for longer than 6 months) o...

I. INTRODUCTION AND SCOPE This document provides guidance to sponsors and applicants submitting investigational new drug applications (INDs), new drug applications (NDAs), biologics licensing applications (BLAs), or supplemental applications on the appropriate...

IoC

IoC C Colin WANG, Ph.D School of Mathematical Sciences, University of Lancaster Institution of Oncology, Chinese Academcy of Medical Science Data Science, Luye Pharma F ...

Fibonacci Sequence The classic Fibonacci sequence is defined by the linear recurrence equation: Which goes like 1, 1, 2, 3, 5, 8, 13, 21, 34, 55, 89, ... In another words, the next number in the sequence is equal to the sum of its two predecessors. The r...

by Seoyoung Koo, Chae Yeon Kim, Jeong-hyeon Lim, Eunyoung Lee, In Young Kim, Young G. Shin, and Hanlim Moon Abstract Antibody-drug conjugates (ADCs) represent a promising class of anticancer therapies with rapidly expanding development. However, regulatory app...

一、概述 单臂临床试验（single arm trial，SAT）是不设立平行对照，采用开放设计，不涉及随机与盲法的一种临床试验设计。 在抗肿瘤治疗领域，为了推动新药及早上市，解决患者未满足的临床急需，对于有效性结果十分突出的抗肿瘤药物，可以依据SAT的试验结果支持上市申请。与公认的金标准——随机对照试验（randomized controlled trial，RCT）结果相比，SAT缺乏平行对照，且往往以替代终点作为主要终点，以快速评估新药的初步有效性和安全性，其结果往往是与历史数据、预先设定的基准或者疾病自然进...

一、背景 传统的临床实践主要基于肿瘤的原发部位和病理组织学分型进行诊断、判断预后以及支持治疗决策。分子生物学和免疫学的研究进步推动了对肿瘤关键异常分子改变的发现，从而改变了医学界对肿瘤的全面认识。某些分子改变可能同时存在于不同组织来源的肿瘤细胞中，导致这些肿瘤具有类似的生物学发生发展机制。因此，业界提出了“不限组织来源的肿瘤”（Tumor-Agnostic）或“泛 肿瘤”（Pan-tumor）（以下简称“泛肿瘤”）的概念。泛肿瘤是从肿瘤起源和病因学等角度，将多种组织来源的肿瘤视为同一类疾病，并且寻求相同的治疗手段。...

IoC E Eric ZHANG, Ph.D, MBA School of Mathematics, Tsinghua University Data Science, Livzon Pharma J Junxian Zhao Clinical Development, Luye Pharma ...